HistoRx Announces Move to State-of-the-Art R&D Complex Adjacent to Yale School of Medicine
Posted on: Monday, 2 May 2005, 12:00 CDT
NEW HAVEN, Conn., May 2 /PRNewswire/ -- HistoRx, Inc., announced today that the company has moved into newly constructed administrative and laboratory space in the recently renovated 300 George Street corporate and research complex, located adjacent to the Yale University School of Medicine in the heart of New Haven's medical and biotechnology district.
"The company is growing very quickly during our first year of operations, and we require additional space designed to meet our specific needs," said Robert A. Curtis, President & CEO of HistoRx. "Since the commercial introduction of our AQUA(TM) quantitative tissue analysis platform in late 2004, we have been experiencing escalating interest from pharmaceutical and biotechnology companies and from academic research laboratories seeking to use tissue to gain critical insights into the underlying biology of many diseases. HistoRx's proprietary AQUA(TM) technology elevates the understanding of tissue proteomics to a new level. This technology can be used to identify relevant biomarkers to assist in drug discovery, to select patients for clinical trials, and, ultimately, to improve patient care by developing new molecular diagnostic reagents for the clinical pathology market."
Recently, HistoRx commercially introduced the first tissue-based quantitative molecular assessment tool for pathology -- the AQUA(TM) Platform for Digital Quantitative Pathology. AQUA(TM) provides the researcher with the ability to localize single or multiple biomarker proteins within subcellular compartments in tissue using a specific antibody, to follow development of the disease state by localizing critical cellular events such as translocation of biomarkers from one subcellular compartment to another, and to closely study relationships of more than one biomarker (through multiplexing) during the disease process.
About HistoRx, Inc.
HistoRx, Inc. is introducing a new generation of advanced quantitative diagnostic products for research and clinical pathology markets based on the company's proprietary integrated tissue analysis platform, AQUA(TM), which the company developed from technology pioneered at the Yale University School of Medicine. Initially, HistoRx is providing contract services to the pharmaceutical and biotechnology industries while selectively licensing its technologies to leading academic and not-for-profit research institutions. Simultaneously, the company is advancing development of proprietary fluorescence-based molecular diagnostic tests for use with its AQUA(TM) platform that will enable biologically based selection of patients who are most likely to benefit from specific therapies. HistoRx is based in New Haven, Conn. http://www.historx.com/
Contact: Robert A. Curtis, President & CEO of HistoRx, Inc., +1-203-498-7500, or bcurtis@historx.com.
HistoRx, Inc.
CONTACT: Robert A. Curtis, President & CEO of HistoRx, Inc.,+1-203-498-7500, or bcurtis@historx.com
Web site: http://www.historx.com/
Source: PRNewswire
Related Articles
- Research and Markets: Personalized Medicine Through Genomic Analysis and Molecular Diagnostics
- Illumina and the Children's Hospital of Eastern Ontario Embark on a Research Collaboration for the Development of Molecular Diagnostics for Newborn Screening
- HistoRx Announces First Installations of New Quantitative in Situ Biomarker Analysis Platform
- Sequenom Reports Positive Outcomes From Two Siemens-Sponsored Molecular Diagnostic Research Studies of MassARRAY(R) Platform
- HistoRx, Inc. Moves to Advance the Development and Commercialization of New Quantitative Tissue Based Diagnostic Tests; Three Industry Leaders Bring New Level of Expertise to Emerging Molecular Diagnostics Company
- Research and Markets: Molecular Diagnostics - Where Is the Market Heading?
- Research and Markets: Global Opportunities in Development of Molecular Diagnostics Analysed.
- Targeted Molecular Diagnostics Announces New Collaboration With Researchers at University of Texas M.D. Anderson Cancer Center
- Research and Markets: Molecular Diagnostics Markets
- Molecular Diagnostics, Inc. Adds Leading Biomolecular Researcher to Its Ranks
 |
 |
User Comments (0)
RSS Feeds